Trial Profile
A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikayce) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Insmed; Transave
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 14 Sep 2009 Positive phase II results presented at ERS 2009, according to a Transave media release.
- 11 Sep 2009 Interim results have been presented at the 19th Annual Congress of the European Respiratory Society.